title: Long-term histological prognosis and serum fibrosis markers in chronic hepatitis C patients treated with interferon.
abstract: BACKGROUND
  Interferon (IFN) therapy is effective in 20-40% of patients with chronic hepatitis C, but the relationship between histological changes and the response to interferon is still unclear. We investigated the long-term histological prognosis and the changes of serum fibrosis markers after interferon therapy relation to the response.
  
  
  RESULTS
  One hundred and eighteen patients with chronic hepatitis C who received interferon therapy were divided into four groups based on the detection of viremia and the serum alanine aminotransferase (ALT) level after treatment. A histological examination was performed by using the histological activity index and the criteria of the METAVIR score. Serum fibrosis markers were used to measure the levels of hyaluronic acid and type IV collagen 7s. Responders, whose serum ALT levels became normal after treatment, demonstrated histological improvement. Histological improvement was more rapid in sustained virological responders with hepatitis C virus (HCV) RNA seronegativity than in biochemical responders with HCV-RNA seropositivity. Only sustained virological responders exhibited histological cure. In partial responders, whose serum ALT levels decreased to less than twice the upper of normal, and non-responders whose serum ALT levels were not reduced, liver fibrosis was unchanged or showed progression. Serum fibrosis markers increased with progression of the histological stage and varied depending on the response to interferon.
  
  
  CONCLUSIONS
  Normalization of serum ALT levels after interferon therapy led to a histological improvement, and that with viral clearance achieved histological cure. Serum fibrosis markers were useful indicators for long-term according to the response of IFN therapy.
authors.affiliation: Second Department of Internal Medicine, Osaka Medical College, Takatsuki, Osaka, Japan. kojima@za3.so-net.ne.jp
authors.forename: H
authors.initials: H
authors.lastname: Kojima
authors.forename: Y
authors.initials: Y
authors.lastname: Hongo
authors.forename: H
authors.initials: H
authors.lastname: Harada
authors.forename: T
authors.initials: T
authors.lastname: Inoue
authors.forename: K
authors.initials: K
authors.lastname: Miyaji
authors.forename: M
authors.initials: M
authors.lastname: Kashiwagi
authors.forename: T
authors.initials: T
authors.lastname: Momose
authors.forename: Y
authors.initials: Y
authors.lastname: Arisaka
authors.forename: H
authors.initials: H
authors.lastname: Fukui
authors.forename: S
authors.initials: S
authors.lastname: Murai
authors.forename: H
authors.initials: H
authors.lastname: Tokita
authors.forename: H
authors.initials: H
authors.lastname: Kamitsukasa
authors.forename: M
authors.initials: M
authors.lastname: Yagura
authors.forename: K
authors.initials: K
authors.lastname: Katsu
mesh_terms: D000328:Adult; D000368:Aged; D001706:Biopsy; D024141:Collagen Type IV / Q000097:blood*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D006820:Hyaluronic Acid / Q000097:blood*; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D008099:Liver / Q000473:pathology; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000473:pathology; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D024141:Collagen Type IV; D016898:Interferon-alpha; D006820:Hyaluronic Acid